Vertex Pharmaceuticals, Inc.

Other

Raytheon Company

William Rowe

Christopher Young

Patricia Nell Hurter

Martin Trudeau

Yuchuan Gong

Yushi Feng

Mariusz Krawiec

Peter D J Grootenhuis

Gregor Zlokarnik

Patrick Raymond Connelly

Adriana Costache

Martyn Botfield

Marinus Jacobus Verwijs

Kirk Overhoff

Alfredo Grossi

Kirk Raymond Dinehart

Alfredo Rene Lara

Neal Pollack

Brian Clebowicz

Dale D Kachuche

Patrick Llorens

James Bynes, Iii

Mariusz Krawlec

Mustafa Amin

Christopher R Young

Patrick Fleming

Patrick Connelly

Fredrick F Van Goor

The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.

Pharmaceutical composition and administrations thereof

Fault injection testing for field programmable gate array (FPGA) devices including: interfacing with a FPGA device under test (DUT); imaging a configuration RAM (CRAM) of the FPGA DUT with a first configuration image to define a first operational function of the FPGA DUT where the CRAM includes a plurality of CRAM bits, injecting a plurality of single event upsets into a portion of the plurality of the CRAM bits while the FPGA DUT is operating; concurrently monitoring operations of the FPGA DUT and a reference FPGA device; comparing outputs of the FPGA DUT with outputs of the reference FPGA device during concurrent operations, and if there is a mismatch between the outputs of the FPGA DUT and the reference FPGA, determining that error events have occurred within the FPGA DUT; and storing the error events and CRAM location data associated with corresponding single event upsets in an error log.

Methods and systems for single-event upset fault injection testing

The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.

Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

A particle analyzer system which operates on-line, real-time and is adaptable to use in process control systems wherein the analysis provides a basis for control of the process. Images of particles are focused onto an array of light sensitive electronic elements. The resulting light pattern is translated into digital data which is retrievably stored in a memory. Analysis of the data by digital logic yields information as to particle counts, size, shape and other physical characteristics. Interim storage in the light sensitive array itself is provided which allows data accumulation using short duration stroboscopic illumination.

Particle analyzer apparatus employing light-sensitive electronic

Three-dimensional images are produced within a transparent cathode-ray tube by directing a plurality of electron beams into a cloud of phosphorescent particles and causing the beams to intersect at a point within the cloud. Each individual beam's current is maintained at less than the threshold of luminescence of the particles but the combined currents may be caused to exceed that threshold by a controlled amount thereby producing light spots of variable brightness at the beam intersection point, which point may be directed into any part of the volume of the cloud. The particle cloud is produced by a high-gradient electric field pump. Use of the pump for particle cloud production in such applications as beam testing is also described.

Three-dimensional display devices

Growing community of inventors

Medford, MA, United States of America

William Rowe